Literature DB >> 15591503

Recombinant human interleukin 10 suppresses gliadin dependent T cell activation in ex vivo cultured coeliac intestinal mucosa.

V M Salvati1, G Mazzarella, C Gianfrani, M K Levings, R Stefanile, B De Giulio, G Iaquinto, N Giardullo, S Auricchio, M G Roncarolo, R Troncone.   

Abstract

BACKGROUND: Enteropathy in coeliac disease (CD) is sustained by a gliadin specific Th1 response. Interleukin (IL)-10 can downregulate Th1 immune responses. AIM: We investigated the ability of recombinant human (rh) IL-10 to suppress gliadin induced Th1 response. PATIENTS AND METHODS: IL-10 RNA transcripts were analysed by competitive reverse transcription-polymerase chain reaction in duodenal biopsies from untreated and treated CD patients, non-coeliac enteropathies (NCE), and controls. CD biopsies were cultured with a peptic-tryptic digest of gliadin with or without rhIL-10. The proportion of CD80+ and CD25+ cells in the lamina propria, epithelial expression of Fas, intraepithelial infiltration of CD3+ cells, as well as cytokine synthesis (interferon gamma (IFN-gamma) and IL-2) were measured. Short term T cell lines (TCLs) obtained from treated CD biopsies cultured with gliadin with or without rhIL-10 were analysed by ELISPOT for gliadin specific production of IFN-gamma.
RESULTS: In untreated CD and NCE, IL-10 RNA transcripts were significantly upregulated. In ex vivo organ cultures, rhIL-10 downregulated gliadin induced cytokine synthesis, inhibited intraepithelial migration of CD3+ cells, and reduced the proportion of lamina propria CD25+ and CD80+ cells whereas it did not interfere with epithelial Fas expression. In short term TCLs, rhIL-10 abrogated the IFN-gamma response to gliadin.
CONCLUSIONS: rhIL-10 suppresses gliadin specific T cell activation. It may interfere with the antigen presenting capacity of lamina propria mononuclear cells as it reduces the expression of CD80. Interestingly, rhIL-10 also induces a long term hyporesponsiveness of gliadin specific mucosal T cells. These results offer new perspectives for therapeutic strategies in coeliac patients based on immune modulation by IL-10.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15591503      PMCID: PMC1774366          DOI: 10.1136/gut.2003.023150

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  36 in total

1.  Direct effects of IL-10 on subsets of human CD4+ T cell clones and resting T cells. Specific inhibition of IL-2 production and proliferation.

Authors:  R de Waal Malefyt; H Yssel; J E de Vries
Journal:  J Immunol       Date:  1993-06-01       Impact factor: 5.422

2.  T cells of the human intestinal lamina propria are high producers of interleukin-10.

Authors:  J Braunstein; L Qiao; F Autschbach; G Schürmann; S Meuer
Journal:  Gut       Date:  1997-08       Impact factor: 23.059

3.  CD4+ T cell down-regulation in human intestinal mucosa: evidence for intestinal tolerance to luminal bacterial antigens.

Authors:  U Y Khoo; I E Proctor; A J Macpherson
Journal:  J Immunol       Date:  1997-04-15       Impact factor: 5.422

4.  Gastric mucosal secretion of interleukin-10: relations to histopathology, Helicobacter pylori status, and tumour necrosis factor-alpha secretion.

Authors:  K Bodger; J I Wyatt; R V Heatley
Journal:  Gut       Date:  1997-06       Impact factor: 23.059

5.  Induction of tolerance by IL-10-treated dendritic cells.

Authors:  K Steinbrink; M Wölfl; H Jonuleit; J Knop; A H Enk
Journal:  J Immunol       Date:  1997-11-15       Impact factor: 5.422

6.  In situ expression of interleukin-10 in noninflamed human gut and in inflammatory bowel disease.

Authors:  F Autschbach; J Braunstein; B Helmke; I Zuna; G Schürmann; Z I Niemir; R Wallich; H F Otto; S C Meuer
Journal:  Am J Pathol       Date:  1998-07       Impact factor: 4.307

7.  A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis.

Authors:  H Groux; A O'Garra; M Bigler; M Rouleau; S Antonenko; J E de Vries; M G Roncarolo
Journal:  Nature       Date:  1997-10-16       Impact factor: 49.962

8.  Altered immune responses in interleukin 10 transgenic mice.

Authors:  A Hagenbaugh; S Sharma; S M Dubinett; S H Wei; R Aranda; H Cheroutre; D J Fowell; S Binder; B Tsao; R M Locksley; K W Moore; M Kronenberg
Journal:  J Exp Med       Date:  1997-06-16       Impact factor: 14.307

9.  Interleukin-10 induces a long-term antigen-specific anergic state in human CD4+ T cells.

Authors:  H Groux; M Bigler; J E de Vries; M G Roncarolo
Journal:  J Exp Med       Date:  1996-07-01       Impact factor: 14.307

10.  Majority of gliadin-specific T-cell clones from celiac small intestinal mucosa produce interferon-gamma and interleukin-4.

Authors:  R Troncone; C Gianfrani; G Mazzarella; L Greco; J Guardiola; S Auricchio; P De Berardinis
Journal:  Dig Dis Sci       Date:  1998-01       Impact factor: 3.199

View more
  33 in total

Review 1.  Celiac disease in pediatric patients with autoimmune hepatitis: etiology, diagnosis, and management.

Authors:  Fabio Panetta; Valerio Nobili; Maria Rita Sartorelli; Raffaele Edo Papa; Francesca Ferretti; Arianna Alterio; Antonella Diamanti
Journal:  Paediatr Drugs       Date:  2012-02-01       Impact factor: 3.022

Review 2.  Proteomic analyses lead to a better understanding of celiac disease: focus on epitope recognition and autoantibodies.

Authors:  Valli De Re; Maria Paola Simula; Vincenzo Canzonieri; Renato Cannizzaro
Journal:  Dig Dis Sci       Date:  2010-07-15       Impact factor: 3.199

3.  Interleukin-10 haplotypes in Celiac Disease in the Spanish population.

Authors:  Concepción Núñez; Diana Alecsandru; Jezabel Varadé; Isabel Polanco; Carlos Maluenda; Miguel Fernández-Arquero; Emilio G de la Concha; Elena Urcelay; Alfonso Martínez
Journal:  BMC Med Genet       Date:  2006-03-31       Impact factor: 2.103

4.  Highly efficient gluten degradation by lactobacilli and fungal proteases during food processing: new perspectives for celiac disease.

Authors:  Carlo G Rizzello; Maria De Angelis; Raffaella Di Cagno; Alessandra Camarca; Marco Silano; Ilario Losito; Massimo De Vincenzi; Maria D De Bari; Francesco Palmisano; Francesco Maurano; Carmen Gianfrani; Marco Gobbetti
Journal:  Appl Environ Microbiol       Date:  2007-05-18       Impact factor: 4.792

Review 5.  Non-dietary forms of treatment for adult celiac disease.

Authors:  Hugh James Freeman
Journal:  World J Gastrointest Pharmacol Ther       Date:  2013-11-06

6.  Induction of antigen-specific tolerance by oral administration of Lactococcus lactis delivered immunodominant DQ8-restricted gliadin peptide in sensitized nonobese diabetic Abo Dq8 transgenic mice.

Authors:  Inge L Huibregtse; Eric V Marietta; Shadi Rashtak; Frits Koning; Pieter Rottiers; Chella S David; Sander J H van Deventer; Joseph A Murray
Journal:  J Immunol       Date:  2009-07-27       Impact factor: 5.422

7.  Gliadin-dependent cytokine production in a bidimensional cellular model of celiac intestinal mucosa.

Authors:  Olimpia Vincentini; Francesca Maialetti; Elena Gonnelli; Marco Silano
Journal:  Clin Exp Med       Date:  2014-12-02       Impact factor: 3.984

8.  Evaluation of 6 candidate genes on chromosome 11q23 for coeliac disease susceptibility: a case control study.

Authors:  Karen Brophy; Anthony W Ryan; Graham Turner; Valerie Trimble; Kunal D Patel; Colm O'Morain; Nicholas P Kennedy; Brian Egan; Eimear Close; Garrett Lawlor; Padraic MacMathuna; Fiona M Stevens; Mohamed Abuzakouk; Conleth Feighery; Dermot Kelleher; Ross McManus
Journal:  BMC Med Genet       Date:  2010-05-17       Impact factor: 2.103

9.  Enzymatic strategies to detoxify gluten: implications for celiac disease.

Authors:  Ivana Caputo; Marilena Lepretti; Stefania Martucciello; Carla Esposito
Journal:  Enzyme Res       Date:  2010-10-07

10.  Bifidobacterium strains suppress in vitro the pro-inflammatory milieu triggered by the large intestinal microbiota of coeliac patients.

Authors:  Marcela Medina; Giada De Palma; Carmen Ribes-Koninckx; Miguel Calabuig; Yolanda Sanz
Journal:  J Inflamm (Lond)       Date:  2008-11-03       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.